Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00641602 |
This study looks at the healing rates in patients with Erosive Esophagitis (EE) when treated with either esomeprazole or lansoprazole
Condition | Intervention | Phase |
---|---|---|
Erosive Esophagitis |
Drug: Esomeprazole Drug: Lansoprazole |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis. |
Estimated Enrollment: | 1000 |
Study Start Date: | December 2002 |
Study Completion Date: | August 2003 |
Primary Completion Date: | August 2003 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Nexium
|
Drug: Esomeprazole
40mg once daily
|
2: Active Comparator
Prevacid
|
Drug: Lansoprazole
30mg once daily
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Astra Zeneca ( Tore Lind, MD - Nexium Medical Science Director ) |
Study ID Numbers: | 322, D9612L00046 |
Study First Received: | March 18, 2008 |
Last Updated: | March 25, 2009 |
ClinicalTrials.gov Identifier: | NCT00641602 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Erosive Esophagitis Nexium Heartburn |
Anti-Infective Agents Esophagitis Pyrosis Digestive System Diseases Esophageal Disorder Gastrointestinal Diseases |
Heartburn Omeprazole Lansoprazole Esophageal Diseases Gastroenteritis |
Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Gastrointestinal Diseases Gastrointestinal Agents Omeprazole Enzyme Inhibitors Pharmacologic Actions |
Esophagitis Digestive System Diseases Therapeutic Uses Anti-Ulcer Agents Esophageal Diseases Lansoprazole Gastroenteritis |